Regression of Subependymal Giant Cell Astrocytoma With Rapamycin in Tuberous Sclerosis Complex
Authors:
- 1 October 2008
- journal article
- other
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 23 (10) , 1238-1239
Abstract
The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2½ months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.Keywords
This publication has 4 references indexed in Scilit:
- Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse modelBMC Dermatology, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Rapamycin causes regression of astrocytomas in tuberous sclerosis complexAnnals of Neurology, 2006
- Effects of Rapamycin in the Eker Rat Model of Tuberous Sclerosis ComplexPediatric Research, 2005